By upholding the health-care overhaul, the Supreme Court keeps on track plans to eliminate a gap in Medicare’s Part D prescription-drug benefit, a popular provision among patients. Does the decision also set a course toward cutting what Medicare itself pays for drugs?
The so-called doughnut hole — designed to reduce the government’s spending on the benefit — has been tough on many seniors. This year, it requires them to pay the costs of their prescriptions when the tab comes in between $2,930 and $6,658. Above that, catastrophic insurance coverage kicks in, and patients typically pay just 5% of their drug costs.
Read the full story: http://tinyurl.com/cfem9rr
Source: The Wall Street Journal
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis
August 5th 2025In this subanalysis of data from the ADjoin trial of lebrikizumab, the interleukin-13 receptor inhibitor that is also a monoclonal antibody showed itself to be effective over the long term in patients with atopic dermatitis on maintenance therapy.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More